Q1 Earnings Forecast for Evolus Issued By Leerink Partnrs

Evolus, Inc. (NASDAQ:EOLS - Free Report) - Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Evolus in a note issued to investors on Wednesday, April 30th. Leerink Partnrs analyst M. Goodman anticipates that the company will earn ($0.24) per share for the quarter. The consensus estimate for Evolus' current full-year earnings is ($0.61) per share. Leerink Partnrs also issued estimates for Evolus' Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at $0.14 EPS and FY2026 earnings at $0.18 EPS.

Other research analysts have also recently issued research reports about the stock. Barclays upped their target price on shares of Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. BTIG Research initiated coverage on shares of Evolus in a research report on Thursday, April 17th. They set a "buy" rating and a $21.00 price objective for the company. HC Wainwright reissued a "buy" rating and issued a $27.00 target price on shares of Evolus in a research report on Thursday, April 10th. Finally, Needham & Company LLC restated a "buy" rating and set a $22.00 price target on shares of Evolus in a research report on Wednesday, April 9th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $23.75.

Evolus Trading Up 1.7 %

EOLS traded up $0.19 during trading hours on Monday, reaching $11.80. The company's stock had a trading volume of 1,351,855 shares, compared to its average volume of 671,124. The stock has a market cap of $760.95 million, a PE ratio of -12.97 and a beta of 1.11. Evolus has a fifty-two week low of $8.67 and a fifty-two week high of $17.82. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. The business's 50-day moving average is $11.89 and its 200-day moving average is $12.67.

Evolus (NASDAQ:EOLS - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.21). Evolus had a negative net margin of 22.33% and a negative return on equity of 847.60%.

Insider Transactions at Evolus

In related news, Director Karah Herdman Parschauer sold 12,888 shares of the stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $12.99, for a total value of $167,415.12. Following the transaction, the director now directly owns 32,183 shares of the company's stock, valued at $418,057.17. This trade represents a 28.59 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Rui Avelar sold 27,904 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total transaction of $370,007.04. Following the completion of the sale, the insider now directly owns 362,467 shares of the company's stock, valued at approximately $4,806,312.42. This trade represents a 7.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 60,575 shares of company stock valued at $794,369. 6.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Evolus

Several hedge funds have recently made changes to their positions in the company. Barclays PLC grew its stake in Evolus by 268.0% during the 3rd quarter. Barclays PLC now owns 93,662 shares of the company's stock worth $1,518,000 after buying an additional 68,213 shares during the last quarter. Principal Financial Group Inc. increased its holdings in shares of Evolus by 9.8% in the 4th quarter. Principal Financial Group Inc. now owns 33,370 shares of the company's stock valued at $368,000 after acquiring an additional 2,989 shares during the period. JPMorgan Chase & Co. raised its position in Evolus by 63.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 169,926 shares of the company's stock valued at $2,753,000 after purchasing an additional 65,972 shares during the last quarter. IFP Advisors Inc boosted its stake in Evolus by 17,440.7% during the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock worth $52,000 after purchasing an additional 4,709 shares during the period. Finally, Rice Hall James & Associates LLC grew its position in Evolus by 4.8% during the 4th quarter. Rice Hall James & Associates LLC now owns 948,281 shares of the company's stock worth $10,469,000 after purchasing an additional 43,381 shares during the last quarter. Hedge funds and other institutional investors own 90.69% of the company's stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.